Your browser doesn't support javascript.
B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose.
Markewitz, Robert; Pauli, Daniela; Dargvainiene, Justina; Steinhagen, Katja; Engel, Sarah; Herbst, Victor; Zapf, Dorinja; Krüger, Christina; Sharifzadeh, Shahpour; Schomburg, Benjamin; Leypoldt, Frank; Rupp, Jan; Görg, Siegfried; Junker, Ralf; Wandinger, Klaus-Peter.
  • Markewitz R; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany. Electronic address: Robert.markewitz@uksh.de.
  • Pauli D; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Dargvainiene J; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Steinhagen K; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Engel S; Department of Anesthesiology and Intensive Care, University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
  • Herbst V; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Zapf D; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Krüger C; Institute for Experimental Immunology, EUROIMMUN AG, Lübeck, Germany.
  • Sharifzadeh S; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Schomburg B; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Leypoldt F; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Rupp J; Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany.
  • Görg S; Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.
  • Junker R; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Wandinger KP; Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein, Kiel, Germany.
Clin Microbiol Infect ; 28(7): 1024.e1-1024.e6, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1783259
ABSTRACT

OBJECTIVES:

To examine the state of B-cell immunity 6 months after the second vaccination against SARS-CoV-2 in comparison to the state observed 2 weeks after vaccination.

METHODS:

Sera of 439 participants, whose immune responses to two doses of an mRNA-based vaccine (BNT162b2 or mRNA-1273) were previously characterized, was examined for anti-S1 IgG and IgA, anti-NCP IgG and neutralizing antibodies (nAb), and antinuclear antibodies (ANA).

RESULTS:

Levels of all examined markers decreased significantly from 2 weeks to 6 months after second vaccination (anti-S1 IgG 3744 ± 2571.4 vs. 253 ± 144 binding antibody units (BAU)/mL; anti-S1 IgA 12 ± 0 vs. 1.98 ± 1.75 optical density (OD) ratio; nAb 100% ± 0% vs. 82% ± 19.3%), the vast majority of participants retaining reactive levels of anti-S1 IgG (436/439) and anti-S1 IgA (334/439) at 6 months. Immune responses were stronger for mRNA-1273 compared with BNT162b2 (anti-S1 IgG 429 ± 289 vs. 243 ± 143 BAU/mL; anti-S1 IgA 5.38 ± 3.91 vs. 1.89 ± 1.53 OD ratio; nAb 90.5% ± 12.6% vs. 81% ± 19.3%). There was no meaningful influence of sex and age on the examined markers. There was a strong correlation between anti-S1 IgG and the surrogate neutralization assay (rho = 0.91, p <0.0001), but not for for IgA and the surrogate neutralization assay (rho = 0.52, p <0.0001). There was a ceiling effect for the association between anti-S1 IgG titres and the inhibition of binding between S1 and ACE2. ANA prevalence was unchanged from 2 weeks to 6 months after the second vaccination (87/498 vs. 77/435), as were the median ANA titres (1160 vs. 1160).

DISCUSSION:

Although the clinical consequences of decreasing anti-SARS-CoV-2 antibody titres cannot be estimated with certainty, a lowered degree of clinical protection against SARS-CoV-2 is possible. Persistently stronger responses to mRNA-1273 suggest that it might confer greater protection than BNT162b2, even 6 months after the second vaccination. Neither examined vaccinations induced ANA within the examined time frame.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Risk factors Topics: Vaccines Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Type of study: Risk factors Topics: Vaccines Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article